Autocrine and paracrine actions of natriuretic peptides in the heart

Pharmacology and Therapeutics

Volumn 101, Issue 2, 2004, Pages 113-129

  D'Souza, Savio P ^a   Davis, Martin ^b   Baxter, Gary F ^c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

cGMP; Guanylyl cyclase; Heart failure; Ischaemia; Myocardial infarction; Natriuretic peptide

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; A 71915; ANANTIN; ARGININE DERIVATIVE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; ATRIAL NATRIURETIC FACTOR DERIVATIVE; ATRIAL NATRIURETIC FACTOR RECEPTOR; BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE RECEPTOR; CALCIUM; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; GUANYLATE CYCLASE; HS 142 1; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PEPTIDE DERIVATIVE; RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; URODILATIN;

ACUTE HEART INFARCTION; APOPTOSIS; AUTOCRINE EFFECT; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CORONARY ARTERY BLOOD FLOW; DOG; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GENE EXPRESSION; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HYPERTROPHY; IMMUNOREACTIVITY; ISCHEMIA; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 0842303041     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2003.11.001     Document Type: Review

References (183)

1. Abell T.J., Richards A.M., Ikram H., Espiner E.A., Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet-derived growth factor. Biochem Biophys Res Commun. 160:1989;1392-1396.
2. Aburaya M., Hino J., Minamino N., Kangawa K., Matsuo H. Isolation and identification of rat brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun. 163:1989;226-232.
3. Aburaya M., Minamino N., Kangawa K., Tanaka K., Matsuo H. Distribution and molecular forms of brain natriuretic peptide in porcine heart and blood. Biochem Biophys Res Commun. 165:1989;872-879.
4. Adachi H., Tomoike H., Nishijima H., Egashira S., Nakamura M. Sustained dilatation of large coronary artery by alpha-human atrial natriuretic peptide in conscious dogs: a comparison with nitroglycerin. Eur J Pharmacol. 161:1989;189-196.
5. Anand-Srivastava M.B., Gutkowska J., Cantin M. The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system. Biochem J. 278:1991;211-217.
6. Bache R.J., Dai X.Z., Schwartz J.S., Chen D.G. Effects of atrial natriuretic peptide in the canine coronary circulation. Circ Res. 62:1988;178-183.
7. Barton M., Beny J.L., d'Uscio L.V., Wyss T., Noll G., Luscher T.F. Endothelium-independent relaxation and hyperpolarization to C-type natriuretic peptide in porcine coronary arteries. J Cardiovasc Pharmacol. 31:1998;377-383.
8. Baxter G.F., Ebrahim Z. Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br J Pharmacol. 135:2002;843-854.
9. Beaulieu P., Cardinal R., Page P., Francoeur F., Tremblay J., Lambert C. Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs. Am J Physiol. 273:1997;H1933-H1940.
10. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 75:1995;725-748.
11. Beltowski J. Guanylin and related peptides. J Physiol Pharmacol. 52:2001;351-375.
12. Bloch K.D., Seidman J.G., Naftilan J.D., Fallon J.T., Seidman C.E. Neonatal atria and ventricles secrete atrial natriuretic factor via tissue-specific secretory pathways. Cell. 47:1986;695-702.
13. Bennett B.D., Bennett G.L., Vitangcol R.V., Jewett J.R., Burnier J., Henzel W., Lowe D.G. Extracellular domain-IgG fusion proteins for three human natriuretic peptide receptors. Hormone pharmacology and application to solid phase screening of synthetic peptide antisera. J Biol Chem. 266:1991;23060- 23067.
14. Best P.J., Burnett J.C., Wilson S.H., Holmes D.R. Jr., Lerman A. Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. Cardiovasc Res. 55:2002;375-384.
15. Boomsma F., van den Meiracker A.H. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res. 51:2001;442-449.
16. Brunner F., Wolkart G. Endothelial NO/cGMP system contributes to natriuretic peptide-mediated coronary and peripheral vasodilation. Microvasc Res. 61:2001;102-110.
17. Brunner F., Wolkart G. Relaxant effect of c-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature. Cardiovasc Res. 51:2001;577-584.
18. Brusq J.M., Mayoux E., Guigui L., Kirilovsky J. Effects of C-type natriuretic peptide on rat cardiac contractility. Br J Pharmacol. 128:1999;206-212.
19. Burnett J.C. Jr., Rubanyi G.M., Edwards B.S., Schwab T.R., Zimmerman R.S., Vanhoutte P.M. Atrial natriuretic peptide decreases cardiac output independent of coronary vasoconstriction. Proc Soc Exp Biol Med. 186:1987;313-318.
20. Cameron V.A., Rademaker M.T., Ellmers L.J., Espiner E.A., Nicholls M.G., Richards A.M. Atrial (ANP) and brain natriuretic peptide (BNP) expression after myocardial infarction in sheep: ANP is synthesized by fibroblasts infiltrating the infarct. Endocrinology. 141:2000;4690-4697.
21. Cao L., Gardner D. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 25:1995;227-234.
22. Casco V.H., Veinot J.P., Kuroski de Bold M.L., Masters R.G., Stevenson M.M., de Bold A.J. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem. 50:2002;799-809.
23. Charles C.J., Espiner E.A., Richards A.M. Cardiovascular actions of ANF: contributions of renal, neurohumoral, and hemodynamic factors in sheep. Am J Physiol. 264:1993;R533-R538.
24. Chauhan S.D., Nilsson H., Ahluwalia A., Hobbs A.J. Release of c-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA. 100:2003;1426-1431.
25. Chinkers M., Garbers D.L. Signal transduction by guanylyl cyclases. Annu Rev Biochem. 60:1991;553-575.
26. Chinkers M., Garbers D.L., Chang M.S., Lowe D.G., Chin H.M., Goeddel D.V., Schulz S. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature. 338:1989;78-83.
27. Chu A., Cobb F.R. Effects of atrial natriuretic peptide on proximal epicardial coronary arteries and coronary blood flow in conscious dogs. Circ Res. 61(4):1987, October;485-491.
28. Clavell A.L., Stingo A.J., Wei C.M., Heublein D.M., Burnett J.C. Jr. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol. 264:1993;R290-R295.
29. ATP channel. Annu Rev Physiol. 62:2000;79-109.
30. Colucci W.S., Elkayam U., Horton D.P., Abraham W.T., Bourge R.C., Johnson A.D., Wagoner L.E., Givertz M.M., Liang C.S., Neibaur M., Haught W.H., LeJemtel T.H. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 343:2000;246-253.
31. Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G., Poole-Wilson P.A., Sutton G.C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 350:1997;1349-1353.
32. 2+, calcineurin and NF-AT. Cell. 96:1999;611-614.
33. de Bold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28:1981;89-94.
34. de Bold A.J., Bruneau B.G., Kuroski de Bold M.L. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res. 31:1996;7-18.
35. de Lemos J.A., Morrow D.A., Bentley J.H., Omland T., Sabatine M.S., McCabe C.H., Hall C., Cannon C.P., Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 345:2001;1014-1021.
36. Delporte C., Winand J., Poloczek P., Von Geldern T., Christophe J. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line. Eur J Pharmacol. 224:1992;183-188.
37. Deprez I., Darmon M.E., Hira M., Adam M., Sanquer S., Teiger E., Chetboul V., Eloit M., Adnot S., Pham I. Adenovirus-mediated transfer of the atrial natriuretic peptide gene in rat pulmonary vascular smooth muscle cells leads to apoptosis. J Lab Clin Med. 137:2001;155-164.
38. D'Souza S.P., Baxter G.F. B-type natriuretic peptide: a good omen in myocardial ischaemia? Heart. 89:2003;707-709.
39. D'Souza S.P., Yellon D.M., Martin C., Schulz R., Heusch G., Onody A., Ferdinandy P., Baxter G.F. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol. 284:2003;H1592-H1600.
40. D'Souza S.P., Yellon D.M., Baxter G.F. Cardioprotective action of B-type natriuretic peptide is NO-dependent. Br J Pharmacol. 138 (Suppl):2003;21P. (abstract).
41. Erdos E.G., Skidgel R.A. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 3:1989;145-151.
42. Espiner E.A., Richards A.M., Yandle T.G., Nicholls M.G. Natriuretic hormones. Endocrinol Metab Clin North Am. 24:1995;481-509.
43. Essayan D.M. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol. 108:2001;671-680.
44. Feil R., Lohmann S.M., de Jonge H., Walter U., Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system. Insights form genetically modified mice. Circ Res. 93:2003;907-916.
45. Fiscus R.R., Tu A.W., Chew S.B. Natriuretic peptides inhibit apoptosis and prolong the survival of serum-deprived PC12 cells. NeuroReport. 12:2001;185-189.
46. Foy S.G., Crozier I.G., Richards A.M., Nicholls M.G., Turner J.G., Frampton C.M., Ikram H. Neurohormonal changes after acute myocardial infarction. Relationships with haemodynamic indices and effects of ACE inhibition. Eur Heart J. 16:1995;770-778.
47. Furuya M., Aisaka K., Miyazaki T., Honbou N., Kawashima K., Ohno T., Tanaka S., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide inhibits intimal thickening after vascular injury. Biochem Biophys Res Commun. 193:1993;248-253.
48. Garthwaite J., Southam E., Boulton C.L., Nielsen E.B., Schmidt K., Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 48:1995;184-188.
49. Goetze J.P., Christoffersen C., Perko M., Arendrup H., Rehfeld J.F., Kastrup J., Nielsen L.B. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 17:2003;1105-1107.
50. Gutkowska J., Nemer M. Structure, expression, and function of atrial natriuretic factor in extraatrial tissues. Endocr Rev. 10:1989;519-536.
51. Hama N., Itoh H., Shirakami G., Nakagawa O., Suga S., Ogawa Y., Masuda I., Nakanishi K., Yoshimasa T., Hashimoto Y. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 92:1995;1558-1564.
52. Hamet P., Tremblay J., Pang S.C., Skuherska R., Schiffrin E.L., Garcia R., Cantin M., Genest J., Palmour R., Ervin F.R. Cyclic GMP as mediator and biological marker of atrial natriuretic factor. J Hypertens Suppl. 4:1986;S49-S56.
53. Hasegawa K., Fujiwara H., Doyama K., Miyamae M., Fujiwara T., Suga S., Mukoyama M., Nakao K., Imura H., Sasayama S. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation. 88:1993;372-380.
54. Hayashi S., Morishita R., Matsushita H., Nakagami H., Taniyama Y., Nakamura T., Aoki M., Yamamoto K., Higaki J., Ogihara T. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 35:2000;237-243.
55. Heinke M.Y., Yao M., Chang D., Einstein R., dos Remedios C.G. Apoptosis of ventricular and atrial myocytes from pacing-induced canine heart failure. Cardiovasc Res. 49:2001;127-134.
56. Hino J., Tateyama H., Minamino N., Kangawa K., Matsuo H. Isolation and identification of human brain natriuretic peptides in cardiac atrium. Biochem Biophys Res Commun. 167:1990;693-700.
57. Hirose M., Furukawa Y., Kurogouchi F., Nakajima K., Miyashita Y., Chiba S. C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. J Pharmacol Exp Ther. 286(1):1998;70-76.
58. Hobbs A.J., Ignarro L.J. Nitric oxide-cyclic GMP signal transduction system. Methods Enzymol. 269:1996;134-148.
59. Hofstaetter B., Taimor G., Inserte J., Garcia-Dorado D., Piper H.M. Inhibition of apoptotic responses after ischemic stress in isolated hearts and cardiomyocytes. Basic Res Cardiol. 97:2002;479-488.
60. Horio T., Nishikimi T., Yoshihara F., Matsuo H., Takishita S., Kanagawa K. Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes. Hypertension. 35:2000;19-24.
61. Ishihara T., Aisaka K., Hattori K., Hamasaki S., Morita M., Noguchi T., Kangawa K., Matsuo H. Vasodilatory and diuretic actions of alpha-human atrial natriuretic peptide (alpha-hANP). Life Sci. 36:1985;1205-1215.
62. John S.W.M., Krege J.H., Oliver P.M., Hagaman J.R., Hodgin J.B., Pang S.C., Flynn T.G., Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 267:1995;679-681. (and erratum Science 1995; 267: 1753).
63. Kambayashi Y., Nakao K., Kimura H., Kawabata T., Nakamura M., Inouye K., Yoshida N., Imura H. Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun. 173:1990;599-605.
64. Kambayashi Y., Nakao K., Mukoyama M., Saito Y., Ogawa Y., Shiono S., Inouye K., Yoshida N., Imura H. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett. 259:1990;341-345.
65. Kangawa K., Fukuda A., Matsuo H. Structural identification of beta- and gamma-human atrial natriuretic polypeptides. Nature. 313:1985;397-400.
66. Keating G.M., Goa K.L. Nesiritide: a review of its use in acute decompensated heart failure. Drugs. 63:2003;47-70.
67. Keilbach A., Ruth P., Hofmann F. Detection of cGMP dependent protein kinase isozymes by specific antibodies. Eur J Biochem. 208:1992;467-473.
68. Kelly R.B. Pathways of protein secretion in eukaryotes. Science. 230:1985;25-32.
69. Kenny A.J., Bourne A., Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J. 291:1993;83-88.
70. Kinnunen P., Vuolteenaho O., Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 132:1993;1961-1970.
71. Kisch B. Electron microscopy of the atrium of the heart. Exp Med Surg. 14:1956;99-112.
72. Koesling D. Studying the structure and regulation of soluble guanylyl cyclase. Methods. 19:1999;485-493.
73. Koglin J., Pehlivanli S., Schwaiblmair M., Vogeser M., Cremer P., vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol. 38:2001;1934-1941.
74. Kojda G., Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res. 41:1999;514-523.
75. Koller K.J., Goeddel D.V. Molecular biology of the natriuretic peptides and their receptors. Circulation. 86:1992;1081-1088.
76. Komatsu Y., Nakao K., Itoh H., Suga S., Ogawa Y., Imura H. Vascular natriuretic peptide. Lancet. 340:1992;622.
77. + channels in cultured vascular smooth muscle cells. Circ Res. 74:1994;471-476.
78. Kuhn M. Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004;. (in press).
79. Kuhn M., Roltwick R., Baba H.A., Perriard J.C., Schmitz W., Ehler E. Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide (GC-A) deficient mice. Heart. 87:2002;368-374.
80. Kuwahara K., Saito Y., Ogawa Y., Tamura N., Ishikawa M., Harada M., Ogawa E., Miyamoto Y., Hamanaka I., Kamitani S., Kajiyama N., Takahashi N., Nakagawa O., Masuda I., Nakao K. Endothelin-1 and cardiotrophin-1 induce brain natriuretic peptide gene expression by distinct transcriptional mechanisms. J Cardiovasc Pharmacol. 31(Suppl 1):1998;S354-S356.
81. Kyriakides Z.S., Markianos M., Michalis L., Antoniadis A., Nikolaou N.I., Kremastinos D.T. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol. 23:2000;285-288.
82. Lainchbury J.G., Espiner E.A., Frampton C.M., Richards A.M., Yandle T.G., Nicholls M.G. Cardiac natriuretic peptides as predictors of mortality. J Intern Med. 241:1997;257-259.
83. Lang R.E., Tholken H., Ganten D., Luft F.C., Ruskoaho H., Unger T. Atrial natriuretic factor - a circulating hormone stimulated by volume loading. Nature. 314:1985;264-266.
84. LaPointe M.C., Wu G., Garami M., Yang X.P., Gardner D.G. Tissue-specific expression of the human brain natriuretic peptide gene in cardiac myocytes. Hypertension. 27:1996;715-722.
85. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med. 339:1998;321-328.
86. Liang F., Atakilit A., Gardner D.G. Integrin dependence of brain natriuretic peptide gene promoter activation by mechanical strain. J Biol Chem. 275:2000;20355-20360.
87. Liu Y., Cigola E., Cheng W., Kajstura J., Olivetti G., Hintze T.H., Anversa P. Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest. 73:1995;771-787.
88. Lohmann S.M., Fischmeister R., Walter U. Signal transduction by cGMP in heart. Basic Res Cardiol. 86:1991;503-514.
89. Lohmann S.M., Vaandrager A.B., Smolenski A., Walter U., De Jonge H.R. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci. 22:1997;307-312.
90. Lohmeier T.E., Mizelle H.L., Reinhart G.A. Role of atrial natriuretic peptide in long-term volume homeostasis. Clin Exp Pharmacol Physiol. 22:1995;55-61.
91. Lopez M.J., Wong S.K., Kishimoto I. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 378:1995;65-68.
92. Lopez M.J., Garbers D.L., Kuhn M. The guanylyl cyclase deficient mouse defines differential pathways of natriuretic peptide signalling. J Biol Chem. 272:1997;23064-23068.
93. Lucas K.A., Pitari G.M., Kazerounian S., Ruiz-Stewart I., Park J., Schulz S., Chepenik K.P., Waldman S.A. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 52:2000;375-414.
94. Ludwig A., Zong X., Stieber J., Hullin R., Hofmann F., Biel M. Two pacemaker channels from human heart with profoundly different activation kinetics. EMBO J. 18:1999;2323-2329.
95. Maack T., Okolicany J., Koh G.Y., Price D.A. Functional properties of atrial natriuretic factor receptors. Semin Nephrol. 13:1993;50-60.
96. MacDonell K.L., Diamond J. Cyclic GMP-dependent protein kinase activation in the absence of negative inotropic effects in the rat ventricle. Br J Pharmacol. 122:1997;1425-1435.
97. Massion P.B., Balligand J.-L. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically-modified mice. J Physiol. 546:2003;63-75.
98. Matsumoto T., Wada A., Tsutamoto T., Omura T., Yokohama H., Ohnishi M., Nakae I., Takahashi M., Kinoshita M. Vasorelaxing effects of atrial and brain natriuretic peptides on coronary circulation in heart failure. Am J Physiol. 276(6 Pt 2):1999;H1935-H1942.
99. McLay J.S., Chatterjee P.K., Mistry S.K., Weerakody R.P., Jardine A.G., McKay N.G., Hawksworth G.M. Atrial natriuretic factor and angiotensin II stimulate nitric oxide release from human proximal tubular cells. Clin Sci (Lond). 89:1995;527-531.
100. Mehats C., Andersen C.B., Filopanti M., Jin S.L., Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab. 13:2002;29-35.
101. Minamino N., Aburaya M., Ueda S., Kangawa K., Matsuo H. The presence of brain natriuretic peptide of 12,000 daltons in porcine heart. Biochem Biophys Res Commun. 155:1988;740-746.
102. Minamino N., Aburaya M., Kojima M., Miyamoto K., Kangawa K., Matsuo H. Distribution of C-type natriuretic peptide and its messenger RNA in rat central nervous system and peripheral tissue. Biochem Biophys Res Commun. 197:1993;326-335.
103. Morishita Y., Sano T., Ando K., Saitoh Y., Kase H., Yamada K., Matsuda Y. Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem Biophys Res Commun. 176:1991;949-957.
104. Morita E., Yasue H., Yoshimura M., Ogawa H., Jougasaki M., Matsumura T., Mukoyama M., Nakao K. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 88:1993;82-91.
105. Morrow D.A., de Lemos J.A., Sabatine M.S., Murphy S.A., Demopoulos L.A., DiBattiste P.M., McCabe C.H., Gibson C.M., Cannon C.P., Braunwald E. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 41:2003;1264-1272.
106. Mukoyama M., Nakao K., Obata K., Jougasaki M., Yoshimura M., Morita E., Hosoda K., Suga S., Ogawa Y., Yasue H. Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun. 180:1991;431-436.
107. Murthy K.S., Teng B.Q., Zhou H., Jin J.G., Grider J.R., Makhlouf G.M. G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor. Am J Physiol Gastrointest Liver Physiol. 278:2000;G974-G980.
108. Nakagawa O., Ogawa Y., Itoh H., Suga S., Komatsu Y., Kishimoto I., Nishino K., Yoshimasa T., Nakao K. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest. 96:1995;1280-1287.
109. Nakamura S., Naruse M., Naruse K., Kawana M., Nishikawa T., Hosoda S., Tanaka I., Yoshimi T., Yoshihara I., Inagami T. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens. 4:1991;909-912.
110. Nakao K., Itoh H., Kambayashi Y., Hosoda K., Saito Y., Yamada T., Mukoyama M., Arai H., Shirakami G., Suga S. Rat brain natriuretic peptide. Isolation from rat heart and tissue distribution. Hypertension. 15:1990;774-778.
111. Nakao K., Mukoyama M., Hosoda K., Suga S., Ogawa Y., Saito Y., Shirakami G., Arai H., Jougasaki M., Imura H. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol. 69:1991;1500-1506.
112. Nir A., Zhang D.F., Fixler R., Burnett J.C. Jr., Eilam Y., Hasin Y. C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. Eur J Pharmacol. 412:2001;195-201.
113. Ogawa Y., Nakao K., Mukoyama M., Hosoda K., Shirakami G., Arai H., Saito Y., Suga S., Jougasaki M., Imura H. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide. Circ Res. 69:1991;491-500.
114. Ogawa Y., Nakao K., Nakagawa O., Komatsu Y., Hosoda K., Suga S., Arai H., Nagata K., Yoshida N., Imura H. Human C-type natriuretic peptide. Characterization of the gene and peptide. Hypertension. 19:1992;809-813.
115. Ohte N., Cheng C.P., Suzuki M., Little W.C. Effects of atrial natriuretic peptide on left ventricular performance in conscious dogs before and after pacing-induced heart failure. J Pharmacol Exp Ther. 291:1999;589-595.
116. Oikawa S., Imai M., Ueno A., Tanaka S., Noguchi T., Nakazato H., Kangawa K., Fukuda A., Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide. Nature. 309:1984;724-726.
117. Okumura K., Yasue H., Fujii H., Kugiyama K., Matsuyama K., Yoshimura M., Jougasaki M., Kikuta K., Kato H., Tanaka H. Effects of brain (B-type) natriuretic peptide on coronary artery diameter and coronary hemodynamic variables in humans: comparison with effects on systemic hemodynamic variables. J Am Coll Cardiol. 25:1995;342-348.
118. Oliver P.M., Fox J.E., Kim R., Rockman H.A., Kim H.-S., Reddick R.L., Pandey K.N., Milgram S.L., Smithies O., Maeda N. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci USA. 94:1997;14730-14735.
119. Olson K.R., Conklin D.J., Farrell A.P., Keen J.E., Takei Y., Weaver L.J., Smith M.P., Zhang Y. Effects of natriuretic peptides and nitroprusside on venous function in trout. Am J Physiol. 273:1997;R527-R539.
120. Opie L.H. Role of cyclic nucleotides in heart metabolism. Cardiovasc Res. 16:1982;483-507.
121. Orlov S.N., Thorin-Trescases N., Dulin N.O., Dam T.V., Fortuno M.A., Tremblay J., Hamet P. Activation of cAMP signaling transiently inhibits apoptosis in vascular smooth muscle cells in a site upstream of caspase-3. Cell Death Differ. 6:1999;661-672.
122. Padilla F., Garcia-Dorado D., Agullo L., Barrabes J.A., Inserte J., Escalona N., Meyer M., Mirabet M., Pina P., Soler-Soler J. Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res. 51:2001;592-600.
123. Porter J.G., Arfsten A., Fuller F., Miller J.A., Gregory L.C., Lewicki J.A. Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA. Biochem Biophys Res Commun. 171:1990;796-803.
124. Potter L.R., Garbers D.L. Dephosphorylation of the guanylyl cyclase-A receptor causes desensitization. J Biol Chem. 267:1992;14531-14534.
125. Potter L.R., Garbers D.L. Protein kinase C-dependent desensitization of the atrial natriuretic peptide receptor is mediated by dephosphorylation. J Biol Chem. 269:1994;14636-14642.
126. Rankin A.J., Swift F.V. The inotropic effect of atrial natriuretic factor in the anesthetized rabbit. Pflugers Arch. 417:1990;353-359.
127. Rastegar M.A., Vegh A., Papp J.G., Parratt J.R. Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs. Cardiovasc Drugs Ther. 14(5):2000;471-479.
128. Redondo J., Bishop J.E., Wilkins M.R. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol. 124:1998;1455-1462.
129. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., Buttimore R.C., Lainchbury J.G., Elliott J.M., Ikram H., Crozier I.G., Smyth D.W. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 97:1998;1921-1929.
130. Richards A.M., Lainchbury J.G., Nicholls M.G., Cameron A.V., Yandle T.G. Dendroaspis natriuretic peptide: endogenous or dubious? Lancet. 359:2002;5-6.
131. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev. 44:1992;479-602.
132. Ruskoaho H., Tholken H., Lang R.E. Increase in atrial pressure releases atrial natriuretic peptide from isolated perfused rat hearts. Pflugers Arch. 407:1986;170-174.
133. Sabatine M.S., Morrow D.A., de Lemos J.A., Gibson C.M., Murphy S.A., Rifai N., McCabe C., Antman E.M., Cannon C.P., Braunwald E. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 105:2002;1760-1763.
134. Sagnella G.A. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin Sci. 95:1998;519-529.
135. Saito Y., Nakao K., Itoh H., Yamada T., Mukoyama M., Arai H., Hosoda K., Shirakami G., Suga S., Minamino N. Brain natriuretic peptide is a novel cardiac hormone. Biochem Biophys Res Commun. 158:1989;360-368.
136. Scarabelli T.M., Knight R.A., Rayment N.B., Cooper T.J., Stephanou A., Brar B.K., Lawrence K.M., Santilli G., Latchman D.S., Baxter G.F., Yellon D.M. Quantitative assessment of cardiac myocyte apoptosis in tissue sections using the fluorescence-based TUNEL technique enhanced with counterstains. J Immunol Methods. 228:1999;23-28.
137. Schirger J.A., Heublein D.M., Chen H.H., Lisy O., Jougasaki M., Wennberg P.W., Burnett J.C. Jr. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc. 74:1999;126-130.
138. Schulz S., Singh S., Bellet R.A., Singh G., Tubb D.J., Chin H., Garbers D.L. The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family. Cell. 58:1989;1155-1162.
139. Schulz R., Cohen M.V., Behrends M., Downey J.M., Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res. 52:2001;181-198.
140. Schulz-Knappe P., Forssmann K., Herbst F., Hock D., Pipkorn R., Forssmann W.G. Isolation and structural analysis of "urodilatin," a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr. 66:1988;752-759.
141. Schweitz H., Vigne P., Moinier D., Frelin C., Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem. 267:1992;13928-13932.
142. 2+ in intact cardiac myocytes. Circ Res. 74:1994;970-978.
143. Shima M., Seino Y., Torikai S., Imai M. Intrarenal localization of degradation of atrial natriuretic peptide in isolated glomeruli and cortical nephron segments. Life Sci. 43:1988;357-363.
144. Shimojo T., Hiroe M., Ishiyama S., Ito H., Nishikawa T., Marumo F. Nitric oxide induces apoptotic death of cardiomyocytes via a cyclic-GMP-dependent pathway. Exp Cell Res. 247:1999;38-47.
145. Silberbach M., Roberts C.T. Jr. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal. 13:2001;221-231.
146. Soleilhac J.M., Lucas E., Beaumont A., Turcaud S., Michel J.B., Ficheux D., Fournie-Zaluski M.C., Roques B.P. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol. 41:1992;609-614.
147. Stone J.A., Backx P.H., ter Keurs H.E. The effect of atrial natriuretic factor on force development in rat cardiac trabeculae. Can J Physiol Pharmacol. 68:1990;1247-1254.
148. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature. 332:1988;78-81.
149. Sudoh T., Maekawa K., Kojima M., Minamino N., Kangawa K., Matsuo H. Cloning and sequence analysis of cDNA encoding a precursor for human brain natriuretic peptide. Biochem Biophys Res Commun. 159:1989;1427-1434.
150. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun. 168:1990;863-870.
151. Suenobu N., Shichiri M., Iwashina M., Marumo F., Hirata Y. Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol. 19:1999;140-146.
152. Supaporn T., Wennberg P.W., Wei C.M., Kinoshita M., Matsuda Y., Burnett J.C. Jr. Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. Clin Sci (Lond). 90:1996;357-362.
153. Suzuki T., Yamazaki T., Yazaki Y. The role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res. 51:2001;489-494.
154. Taimor G., Hofstaetter B., Piper H.M. Apoptosis induction by nitric oxide in adult cardiomyocytes via cGMP-signaling and its impairment after simulated ischemia. Cardiovasc Res. 45:2000;588-594.
155. Takagi G., Kiuchi K., Endo T., Yamamoto T., Sato N., Nejima J., Takano T. Alpha-human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/reperfusion in dogs. J Cardiovasc Pharmacol. 36:2000;22-30.
156. Talwar S., Squire I.B., Downie P.F., Davies J.E., Ng L.L. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart. 84:2000;421-424.
157. +-ATPase in cyclic GMP-mediated relaxation of canine pulmonary artery smooth muscle cells. Br J Pharmacol. 122:1997;112-116.
158. Tamura N., Itoh H., Ogawa Y., Nakagawa O., Harada M., Chun T.H., Suga S., Yoshimasa T., Nakao K. cDNA cloning and gene expression of human type Ialpha cGMP-dependent protein kinase. Hypertension. 27:1996;552-557.
159. Tamura N., Ogawa Y., Chusho H., Nakamura K., Nakao K., Suda M., Kasahara M., Hashimoto R., Katsuura G., Mukoyama M., Itoh H., Saito Y., Tanaka I., Otani H., Katsuki M., Nakao K. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA. 97:2000;4239-4244.
160. Tateishi J., Masutani M., Ohyanagi M., Iwasaki T. Transient increase in
161. Tokola H., Hautala N., Marttila M., Magga J., Pikkarainen S., Kerkela R., Vuolteenaho O., Ruskoaho H. Mechanical load-induced alterations in B-type natriuretic peptide gene expression. Can J Physiol Pharmacol. 79:2001;646-653.
162. Tomaru Ki K., Arai M., Yokoyama T., Aihara Y., Sekiguchi Ki K., Tanaka T., Nagai R., Kurabayashi M. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 34:2002;649-659.
163. Toth M., Vuorinen K.H., Vuolteenaho O., Hassinen I.E., Uusimaa P.A., Leppaluoto J., Ruskoaho H. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol. 266:1994;H1572-H1580.
164. Tsuruda T., Boerrigter G., Huntley B.K., Noser J.A., Cataliotti A., Costello-Boerrigter L.C., Chen H.H., Burnett J.C. Jr. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 91:2002;1127-1134.
165. Vaandrager A.B., De Jonge H.R. Signalling by cGMP-dependent protein kinases. Mol Cell Biochem. 157:1996;23-30.
166. van den Akker F. Structural insights into the ligand binding domains of membrane bound guanylyl cyclases and natriuretic peptide receptors. J Mol Biol. 311:2001;923-937.
167. Vaxelaire J.F., Laurent S., Lacolley P., Briand V., Schmitt H., Michel J.B. Atrial natriuretic peptide decreases contractility of cultured chick ventricular cells. Life Sci. 45(1):1989;41-48.
168. Vuolteenaho O., Arjamaa O., Ling N. Atrial natriuretic polypeptides (ANP): rat atria store high molecular weight precursor but secrete processed peptides of 25-35 amino acids. Biochem Biophys Res Commun. 129:1985;82-88.
169. Weber W., Fischli W., Hochuli E., Kupfer E., Weibel E.K. Anantin - a peptide antagonist of the atrial natriuretic factor (ANF). I. Producing organism, fermentation, isolation and biological activity. J Antibiot (Tokyo). 44:1991;164-171.
170. Wei C.M., Hu S., Miller V.M., Burnett J.C. Jr. Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. Biochem Biophys Res Commun. 205(1):1994, November 30;765-771.
171. White R.E., Lee A.B., Shcherbatko A.D., Lincoln T.M., Schonbrunn A., Armstrong D.L. Potassium channel stimulation by natriuretic peptides through cGMP-dependent dephosphorylation. Nature. 361:1993;263-266.
172. Wiley K.E., Davenport A.P. Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br J Pharmacol. 133:2001;568-574.
173. Wong F., Blendis L. Pathophysiology of sodium retention and ascites formation in cirrhosis: role of atrial natriuretic factor. Semin Liver Dis. 14:1994;59-70.
174. Woods R.L. Vasoconstrictor actions of atrial natriuretic peptide in the splanchnic circulation of anaesthetised dogs. Am J Physiol. 275:1998;R1822- R1832.
175. Woods R.L. Atrial, B-type and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs. Am J Physiol. 276:1999;R1443-R1452.
176. Wright R.S., Wei C.M., Kim C.H., Kinoshita M., Matsuda Y., Aarhus L.L., Burnett J.C. Jr., Miller W.L. C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. J Am Coll Cardiol. 28:1996;1031-1038.
177. Wu C.F., Bishopric N.H., Pratt R.E. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem. 272:1997;14860-14866.
178. Yamamoto K., Ikeda U., Shimada K. Natriuretic peptides modulate nitric oxide synthesis in cytokine-stimulated cardiac myocytes. J Mol Cell Cardiol. 29:1997;2375-2382.
179. Yan W., Wu F., Morser J., Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA. 97:2000;8525-8529.
180. Yanagisawa A., Osborne J.A., Stahl G.L., Lefer A.M. Coronary vascular actions of synthetic atrial natriuretic factor in isolated vascular preparations. J Cardiovasc Pharmacol. 10:1987;320-326.
181. Yandle T.G. Biochemistry of natriuretic peptides. J Intern Med. 235:1994;561-576.
182. Zeidel M.L. Hormonal regulation of inner medullary collecting duct sodium transport. Am J Physiol. 265:1993;F159-F173.
183. Zellner C., Protter A.A., Ko E., Pothireddy M.R., DeMarco T., Hutchison S.J., Chou T.M., Chatterjee K., Sudhir K. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol. 276:1999;H1049-H1057.